Furthest along
2 in Phase 1
Drugs
2
in active trials · 3 in all
Trials
2 active
4 since 2021
Drugs2
| Drug | How it works | Partner | Stage
Sources: FDA: the drug development process, ClinicalTrials.gov glossary | Next date
| Details |
|---|---|---|---|---|---|
In vivo CAR-T for blood cancers, target not disclosed |
Phase 1 | 15 Oct 2028Phase 1 trial completes | |||
| How it works | Reprograms the patient's own immune T cells | ||||
| Next date | 15 Oct 2028 · Phase 1 trial completes | ||||
| Also tested for | Relapsed or Refractory Hematologic Malignancies | ||||
| Open drug page | |||||
— |
Phase 1 | — | |||
| Also tested for | High-grade Glioma, WHO Grade Ⅳ Glioma | ||||
| Open drug page | |||||
About
- No active trial
- DIT309
- SEC filings
- None: Tcelltech is private
- Sources
- ClinicalTrials.gov updated 16 Nov 2026 Industry-sponsored drug trials since 2021